PBMWW NASDAQ

Psyence Biomedical Ltd. focuses on developing psychedelic medications derived from botanical psilocybin. The company is also investigating the use of natural psilocybin to alleviate adjustment disorder in patients with incurable cancer who are undergoing palliative care. Its primary product candidate, PEX010, is a capsule containing naturally sourced psilocybin, which is currently undergoing a Phase IIb clinical study. PEX010 aims to treat anxiety, depression, and related conditions such as post-traumatic stress disorder, stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial, examining PEX010's efficacy in psilocybin-assisted psychotherapy for adjustment disorder caused by incurable cancer. Headquartered in Toronto, Canada, the company operates as a subsidiary of Psyence Group Inc.